Are autoantibodies the targets of B-cell-directed therapy?

被引：0
|
作者：
David S. Pisetsky
Amrie C. Grammer
Tony C. Ning
Peter E. Lipsky
机构：
[1] Medical Research Service,Department of Medicine and Immunology
[2] Durham VA Hospital,Division of Rheumatology and Immunology
[3] Duke University Medical Center,undefined
来源：
Nature Reviews Rheumatology | 2011年 / 7卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Autoantibodies, produced by autoreactive B cells, are involved in the pathology of rheumatic diseases including systemic lupus erythematosus (SLE). Modulation of B-cell function by inhibiting cytokines active on B cells or even eliminating B-cell populations can effectively treat SLE and other diseases. So far so simple, yet—as explored in this Perspective—the relationships between the effects of such therapies on B cells, the levels of individual autoantibodies, and clinical outcomes are fiendishly complex. Better knowledge of B-cell biology is needed to understand the effects of agents that target B cells, and to increase their efficacy.
引用
收藏
页码：551 / 556
页数：5
相关论文
共 50 条
  • [21] Prolonged survival of guinea-pig-to-rat heart xenografts following complement depletion and B-cell-directed immunosuppression by malononitrilamide
    Vilsendorf, AMZ
    Nagel, E
    Link, C
    Jörns, A
    Köhl, J
    TRANSPLANTATION PROCEEDINGS, 2000, 32 (05) : 864 - 865
  • [22] Alteration of B cell homeostasis after splenectomy -: Implications for B cell directed therapy
    Gamboa, L. Martinez
    Mei, H.
    Reiter, K.
    Kemnitz, K.
    Emmerich, F.
    Salama, A.
    Hansen, A.
    Doerner, T.
    ANNALS OF THE RHEUMATIC DISEASES, 2007, 66 : 158 - 158
  • [23] Loss of Intra-Islet CD20 Expression May Complicate Efficacy of B-Cell-Directed Type 1 Diabetes Therapies
    Serreze, David V.
    Chapman, Harold D.
    Niens, Marijke
    Dunn, Robert
    Kehry, Marilyn R.
    Driver, John P.
    Haller, Michael
    Wasserfall, Clive
    Atkinson, Mark A.
    DIABETES, 2011, 60 (11) : 2914 - 2921
  • [24] B Cell homeostasis in autoimmune thrombocytopenia:: Effects of splenectomy and implications for B Cell directed therapy
    Martinez, Gamboa L.
    Mei, H.
    Reiter, K.
    Kemnitz, K.
    Emmerich, F.
    Salama, A.
    Doerner, T.
    ZEITSCHRIFT FUR RHEUMATOLOGIE, 2007, 66 : 22 - 23
  • [25] Matrix MetalloproteinasesNovel Targets for Directed Cancer Therapy
    Anita E. Yu
    Robert E. Hewitt
    Edward W. Connor
    William G. Stetler-Stevenson
    Drugs & Aging, 1997, 11 : 229 - 244
  • [26] New Targets for Antibody Therapy of Pediatric B Cell Lymphomas
    van Vuren, Annelies
    Meyer-Wentrup, Friederike
    PEDIATRIC BLOOD & CANCER, 2014, 61 (12) : 2158 - 2163
  • [27] Persistent Mixed Cryoglobulinemia Despite Successful Treatment of Hepatitis C, Aggressive B-Cell-Directed Therapies, and Long-term Plasma Exchanges
    Pelletier, Karyne
    Royal, Virginie
    Mongeau, Frederic
    Meunier, Rosalie-Selene
    Dion, Daniel
    Jao, Kevin
    Troyanov, Stephan
    KIDNEY INTERNATIONAL REPORTS, 2019, 4 (08): : 1194 - 1198
  • [28] Translational Mini-Review Series on B Cell-Directed Therapies: B cell-directed therapy for autoimmune diseases
    Hu, C.
    Wong, F. S.
    Wen, L.
    CLINICAL AND EXPERIMENTAL IMMUNOLOGY, 2009, 157 (02): : 181 - 190
  • [29] Elevated Fab glycosylation of autoantibodies maintained during B cell depletion therapy
    Anika M. Valk
    Jana Koers
    Ninotska I. L. Derksen
    Laura Hogenboom
    Zoé van Kempen
    Joep Killestein
    Abraham Rutgers
    Peter Heeringa
    Barbara Horváth
    Taco W. Kuijpers
    S. Marieke van Ham
    Anja ten Brinke
    Diane van der Woude
    René E. M. Toes
    Nicolaas A. Bos
    Theo Rispens
    Scientific Reports, 15 (1)
  • [30] B cell-directed therapy in rheumatoid arthritis clinical experience
    Panayi, GS
    JOURNAL OF RHEUMATOLOGY, 2005, 32 : 19 - 24
12345